IFN-γ1b (human recombinant)

Home
Ligands
IFN-γ1b (human recombinant)

GtoPdb Ligand ID: 8341

Synonyms: Actimmune®. | IFNγ2a

IFN-γ1b (human recombinant) is an approved drug (FDA (1999))

Compound class: Peptide or derivative

Comment: This is a recombinant analogue of human interferon gamma (IFN-γ) produced in E.coli and is therefore not glycosylated.

No information available.

No information available.

Summary of Clinical Use
IFN-γ1b is approved to treat chronic granulomatous disease (CGD) [3] and severe, malignant osteopetrosis [2]. In 2007, the EMA granted orphan designation for the use of interferon gamma to treat idiopathic pulmonary fibrosis. The product also has EMA and FDA orphan designation for the treatment of Friedreich’s ataxia [4]..

Summary of Clinical Use

IFN-γ1b is approved to treat chronic granulomatous disease (CGD) [3] and severe, malignant osteopetrosis [2]. In 2007, the EMA granted orphan designation for the use of interferon gamma to treat idiopathic pulmonary fibrosis. The product also has EMA and FDA orphan designation for the treatment of Friedreich’s ataxia [4]..

Mechanism Of Action and Pharmacodynamic Effects
IFN-γ1b activates interferon receptors and induces expression of genes with antiviral, antibacterial, antiapoptotic, antitumor, and immunomodulatory effects [1,5]. The molecular mechanism underlying the clinical benefit of IFN-γ1b therapy is poorly understood.

Mechanism Of Action and Pharmacodynamic Effects

IFN-γ1b activates interferon receptors and induces expression of genes with antiviral, antibacterial, antiapoptotic, antitumor, and immunomodulatory effects [1,5]. The molecular mechanism underlying the clinical benefit of IFN-γ1b therapy is poorly understood.